checkAd
    Startseite > Aktien > Clene > Nachrichten
    Clene Aktie
    0,4145
     
    USD
    -5,60 %
    -0,0246 USD
    Letzter Kurs 02:00:00 NYSE
    0,3980
     
    USD
    400 STK
    Geldkurs 11.06.24
    0,4226
     
    USD
    400 STK
    Briefkurs 11.06.24
    ISIN: US1856341029 · WKN: A2QE9Y · SYM: CLNN · USA

    Neueste Nachrichten

    Clene to Present at the Emerging Growth Conference
    05.06.24 · globenewswire · Clene
    Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8 in ALS (ACT-EAP)
    28.05.24 · globenewswire · Clene
    Clene to Present at Upcoming May Conferences
    14.05.24 · globenewswire · Clene
    Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
    08.05.24 · globenewswire · Clene
    Evidence for Clene’s CNM-Au8 as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
    16.04.24 · globenewswire · Clene
    Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8
    15.03.24 · globenewswire · Clene
    Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
    13.03.24 · globenewswire · Clene
    Clene to Present at the 36th Annual ROTH Conference
    07.03.24 · globenewswire · Clene
    Clene Presents Clinical Results of CNM-Au8 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
    29.02.24 · globenewswire · Clene
    Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs
    22.02.24 · globenewswire · Clene
    Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8 Treatment in VISIONARY-MS Trial Long-Term Open Label Extension
    08.01.24 · globenewswire · Clene
    Clene Provides Update on ALS Clinical Development Meeting With FDA
    21.12.23 · globenewswire · Clene